GPs in England to be Paid Bonuses to Maximize Weight-Loss Drug Prescriptions

This incentive, which will be added to the contracts of GPs in England from April, also includes around £1,000 ($1,330) a year for referring patients to weight management programs. Ministers claim the move is designed to improve access to effective treatments and shift the country’s National Health Service (NHS) toward prevention. Incentive payments are already a routine part of GP contracts in the UK, but this is the first time that weight-loss drugs have been included.

Currently, access to Mounjaro – a weight-loss injection manufactured by the Eli Lilly pharmaceutical company – is tightly restricted on the NHS. Available only to patients with severe obesity, eligibility is planned to expand next year. By 2028, around 220,000 patients are expected to receive the drug through the NHS. Another injectable weight loss medication, Wegovy, manufactured by Novo Nordisk, is also available, but prescribed through specialist services rather than GPs. More than one million people in England are thought to be using weight-loss injections overall, with the vast majority paying for them privately.

Ultimately, however, far from being the gamechanger that they are aggressively being promoted as, weight-loss drugs are just the latest overhyped pharma fad. It would be naïve to expect them to solve a nation’s health problems anytime soon. Instead, they’re simply another distraction that puts more money in pharma pockets but deliberately avoids addressing real, long-term solutions to obesity and overweight.

To learn about the dangers of weight-loss drugs, see this article on our website.